Cullinan Therapeutics(CGEM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CGEM Cullinan Therapeutics

Trading 10-05 11:38:48 EDT

15.48

-0.03

-0.19%

High15.65	Low15.13	Vol176.18K
Open15.58	D1 Closing15.51	Amplitude3.35%
Mkt Cap996.21M	Tradable Cap744.32M	Total Shares64.35M
T/O2.71M	T/O Rate0.37%	Tradable Shares48.08M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CGEM","market":"US","secType":"STK","nameCN":"Cullinan Therapeutics","latestPrice":15.48,"timestamp":1791214720400,"preClose":15.51,"halted":0,"volume":176180,"delay":0,"changeRate":-0.001934235976789127,"floatShares":48082800,"shares":64354694,"eps":-3.468035,"marketStatus":"Trading","change":-0.03,"latestTime":"10-05 11:38:48 EDT","open":15.58,"high":15.649,"low":15.13,"amount":2711405.61932,"amplitude":0.033462,"askPrice":15.49,"askSize":200,"bidPrice":15.44,"bidSize":101,"shortable":3,"etf":0,"ttmEps":-3.468035,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791230400000},"marketStatusCode":2,"adr":0,"listingDate":1610082000000,"exchange":"NASDAQ","adjPreClose":15.51,"preHourTrading":{"tag":"盘前","latestPrice":15.6,"preClose":15.51,"latestTime":"09:29 EDT","volume":2353,"amount":36508.049149,"timestamp":1791206999909,"change":0.09,"changeRate":0.005803,"amplitude":0.043198},"postHourTrading":{"tag":"盘后","latestPrice":15.51,"preClose":15.51,"latestTime":"19:30 EDT","volume":32442,"amount":503185.8937,"timestamp":1790983803944,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.484678,"impliedVol":0.5449,"impliedVolPercentile":0.2072},"requestUrl":"/m/hq/s/CGEM","defaultTab":"news","newsList":[{"id":"2672103667","title":"Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE) and Cullinan Management (CGEM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2672103667","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672103667?lang=en_us&edition=fundamental","pubTime":"2026-10-02 22:00","pubTimestamp":1790949616,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Monte Rosa Therapeutics (GLUE) and Cullinan Manageme...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-monte-rosa-therapeutics-glue-and-cullinan-management-cgem-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-monte-rosa-therapeutics-glue-and-cullinan-management-cgem-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","BK4539","BK4588","BK4581","BK4137","LABU","LU0128526141.USD","BK4139","CGEM","HCSG","GLUE","LU0029874061.USD","BK4585","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672716458","title":"Cullinan Therapeutics Price Target Maintained with a $35.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2672716458","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672716458?lang=en_us&edition=fundamental","pubTime":"2026-10-02 18:42","pubTimestamp":1790937720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CGEM/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672716160","title":"Cullinan Management Advances NDA for Zipalertinib Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2672716160","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672716160?lang=en_us&edition=fundamental","pubTime":"2026-10-02 18:33","pubTimestamp":1790937182,"startTime":"0","endTime":"0","summary":"An update from Cullinan Management ( ($CGEM) ) is now available. On October 1, 2026, Cullinan Therapeutics announced it had initiated a New Drug Ap...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cullinan-management-advances-nda-for-zipalertinib-combination?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cullinan-management-advances-nda-for-zipalertinib-combination?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGEM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672154237","title":"Cullinan Initiates FDA NDA Submission for Zipalertinib Plus Chemotherapy Under RTOR Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2672154237","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672154237?lang=en_us&edition=fundamental","pubTime":"2026-10-02 18:03","pubTimestamp":1790935425,"startTime":"0","endTime":"0","summary":"Cullinan initiates FDA NDA submission for zipalertinib plus chemotherapy under RTOR programCullinan initiated an FDA Real-Time Oncology Review NDA submission for zipalertinib with platinum chemotherap","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDLbYh2Cs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672790775","title":"Cullinan Starts FDA Submission for Zipalertinib-Chemotherapy Combo in Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2672790775","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672790775?lang=en_us&edition=fundamental","pubTime":"2026-10-02 16:10","pubTimestamp":1790928630,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics  has started submitting its new drug application to the US Food and Drug Administration for zipalertinib plus platinum-based chemotherapy in previously untreated non-small cell lung cancer,  the company said late Thursday.The filing is being reviewed under the FDA's Real-Time Oncology Review program, which allows regulators to assess clinical data ahead of a full application.The submission is supported by results from a phase 3 trial showing a significant progression-free survival benefit over chemotherapy alone, the company said.Cullinan expects to complete the regulatory submission by year-end 2026.The company is eligible for milestone payments of $30 million and $100 million tied to potential second-line and first-line approvals, respectively, it said.Cullinan said Zipalertinib remains an investigational drug and has not been approved by any health authority.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4585","CGEM","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672985277","title":"Cullinan Therapeutics initiates NDA for Zipalertinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2672985277","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672985277?lang=en_us&edition=fundamental","pubTime":"2026-10-02 07:35","pubTimestamp":1790897712,"startTime":"0","endTime":"0","summary":"The company stated: “Cullinan Therapeutics (CGEM) announced the initiation of a New Drug Application submission to the U.S. Food and Drug Administr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cullinan-therapeutics-initiates-nda-for-zipalertinib-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cullinan-therapeutics-initiates-nda-for-zipalertinib-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672988147","title":"New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line Egfr Exon 20 Insertion Mutation Nsclc for Review Under FDA Real-Time Oncology Review Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2672988147","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672988147?lang=en_us&edition=fundamental","pubTime":"2026-10-02 07:30","pubTimestamp":1790897400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nTUA6CX3DB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CGEM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670440157","title":"Analysts Offer Insights on Healthcare Companies: AMN Healthcare Services (AMN) and Cullinan Management (CGEM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2670440157","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670440157?lang=en_us&edition=fundamental","pubTime":"2026-09-25 20:50","pubTimestamp":1790340613,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AMN Healthcare Services (AMN) and Cullinan Managemen...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amn-healthcare-services-amn-and-cullinan-management-cgem-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amn-healthcare-services-amn-and-cullinan-management-cgem-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4581","BK4585","BK4196","BK4139","CGEM","XLV","LABU","XBI","AMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670441844","title":"Cullinan Therapeutics price target raised to $35 from $30 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2670441844","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670441844?lang=en_us&edition=fundamental","pubTime":"2026-09-25 18:35","pubTimestamp":1790332539,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on Cullinan Therapeutics (CGEM) to $35 from $30 and keeps a Buy rating on the shares. The company ye...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cullinan-therapeutics-price-target-raised-to-35-from-30-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cullinan-therapeutics-price-target-raised-to-35-from-30-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670441106","title":"Cullinan Therapeutics Price Target Maintained with a $40.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2670441106","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670441106?lang=en_us&edition=fundamental","pubTime":"2026-09-25 17:59","pubTimestamp":1790330340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CGEM/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670412443","title":"US Research Roundup-Chevron, Exxon Mobil, GoDaddy","url":"https://stock-news.laohu8.com/highlight/detail?id=2670412443","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670412443?lang=en_us&edition=fundamental","pubTime":"2026-09-25 14:58","pubTimestamp":1790319529,"startTime":"0","endTime":"0","summary":"US RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddySept 25 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several US-listed companies, including Chevron, Exxon Mobi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nL4N45H0CH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RSPC","AEE","BNY","KMX","TRUC","PYPL","SO","GPOR","CRL","COST","TRUN","GEN","HELX","GRAL","ACAD","NTRA","CDNL","XLP","ALM","CF","CVX","UGE","OKTA","DRI","DMRA","CGEM","XOM","AXGN","CNK","LMRI","P","EMR","UPW","GDDY","FFBC","INFQ","GXPE","CRK","FUL","OILT","KNF","CMCSA","ANDG","STZ","FSTA","META","OBK","MMM","AKAM","CPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670052490","title":"Matt Phipps Reiterates Buy on Cullinan Oncology, Citing Pullback-Driven Upside and Upcoming Q4 Clinical Data Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2670052490","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670052490?lang=en_us&edition=fundamental","pubTime":"2026-09-25 03:35","pubTimestamp":1790278521,"startTime":"0","endTime":"0","summary":"William Blair analyst Matt Phipps has reiterated their bullish stance on CGEM stock, giving a Buy rating today. Matt Phipps has given his Buy ratin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/matt-phipps-reiterates-buy-on-cullinan-oncology-citing-pullback-driven-upside-and-upcoming-q4-clinical-data-catalysts-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/matt-phipps-reiterates-buy-on-cullinan-oncology-citing-pullback-driven-upside-and-upcoming-q4-clinical-data-catalysts-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGEM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670388497","title":"Cullinan Therapeutics share weakness provides buying opportunity, says TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2670388497","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670388497?lang=en_us&edition=fundamental","pubTime":"2026-09-25 01:15","pubTimestamp":1790270115,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics (CGEM) enters Q4 with a catalyst-rich roadmap across its autoimmune and AML programs, as longer follow-up and multi-dose data...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cullinan-therapeutics-share-weakness-provides-buying-opportunity-says-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cullinan-therapeutics-share-weakness-provides-buying-opportunity-says-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COWN","CGEM","BK4127","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669494305","title":"Cullinan falls after pushing rheumatoid arthritis data to December","url":"https://stock-news.laohu8.com/highlight/detail?id=2669494305","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669494305?lang=en_us&edition=fundamental","pubTime":"2026-09-24 23:30","pubTimestamp":1790263812,"startTime":"0","endTime":"0","summary":"Shares of Cullinan Therapeutics (CGEM) after the company said CLN-978 data in systemic lupus erythematosus, difficult-to-treat rheumatoid arthritis...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cullinan-falls-after-pushing-rheumatoid-arthritis-data-to-december-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cullinan-falls-after-pushing-rheumatoid-arthritis-data-to-december-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGEM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669462171","title":"Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2669462171","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669462171?lang=en_us&edition=fundamental","pubTime":"2026-09-24 19:00","pubTimestamp":1790247600,"startTime":"0","endTime":"0","summary":"Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA and Sjgren’s disease in December CLN-049 (FLT3 TCE) upda","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/24/3368185/0/en/cullinan-therapeutics-highlights-fourth-quarter-2026-milestones-across-immunology-and-oncology-t-cell-engager-portfolio.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE","BK4139","RA","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669956436","title":"Small U.S. Stocks Close Lower; Cullinan Therapeutics Posts Biggest Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2669956436","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669956436?lang=en_us&edition=fundamental","pubTime":"2026-09-24 04:20","pubTimestamp":1790194800,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of small-cap companies declined Wednesday, as the Russell 2000 Index dropped 1.8%, and the S&P Small Cap 600 Index was down 1.1%.Among companies with a market value of $1 billion to $6.7 billion, Cullinan Therapeutics Inc. was the biggest laggard during the session, dropping 22%, followed by shares of Alkami Technology Inc., which dropped 19%. Shares of Rapport Therapeutics Inc. dropped 18%, Voyager Technologies Inc. shares tumbled 16%, and InnovAge Holding Corp. plunged 16%.Fastly Inc. Cl A was the best performer, surging 14%, followed by Securitize Corp., which surged 10%. ACM Research Inc. Cl A shares jumped 6.4%, Klaviyo Inc. jumped 5.7%, and shares of Allient Inc. jumped 5.1%.Major U.S. stock indexes fell Wednesday with the Nasdaq Composite Index falling 1.1%. Meanwhile, the S&P 500 Index dropped 0.8%, and the Dow Jones Industrial Average dropped 0.7%.Data source: Dow Jones Market Data, FactSet","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669433451","title":"Cullinan Therapeutics Down over 20%, on Track for Record Percent Decrease","url":"https://stock-news.laohu8.com/highlight/detail?id=2669433451","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669433451?lang=en_us&edition=fundamental","pubTime":"2026-09-24 02:32","pubTimestamp":1790188320,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics, Inc.  is currently at $17.31, down $4.36 or 20.12%--Would be lowest close since Aug. 3, 2026, when it closed at $16.25--Would be largest percent decrease on record --Snaps a two day winning streak--Down 21.57% month-to-date; on pace for worst month since June 2024, when it fell 25.79%--Up 67.25% year-to-date--Down 67.6% from its all-time closing high of $53.42 on March 10, 2021--Up 187.06% from 52 weeks ago , when it closed at $6.03--Down 24.58% from its 52-week closing high of $22.95 on Aug. 25, 2026--Up 201.04% from its 52-week closing low of $5.75 on Oct. 2, 2025--Traded as low as $17.12; lowest intraday level since Aug. 6, 2026, when it hit $17.06--Down 21% at today's intraday low; largest intraday percent decrease on record All data as of 2:23:48 PM ETSource: Dow Jones Market Data, FactSet","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669811162","title":"Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2669811162","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669811162?lang=en_us&edition=fundamental","pubTime":"2026-09-22 00:00","pubTimestamp":1790006400,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Sept.  21, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/21/3365707/0/en/cullinan-therapeutics-to-participate-in-the-stifel-2026-virtual-immunology-and-inflammation-forum.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM","FET","BK4139","BK4179"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667464294","title":"Cullinan Management (CGEM) Gets a Buy from Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2667464294","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667464294?lang=en_us&edition=fundamental","pubTime":"2026-09-15 20:15","pubTimestamp":1789474528,"startTime":"0","endTime":"0","summary":"In a report released today, Robert Driscoll from Wedbush reiterated a Buy rating on Cullinan Management, with a price target of $42.00. Driscoll co...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cullinan-management-cgem-gets-a-buy-from-wedbush-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cullinan-management-cgem-gets-a-buy-from-wedbush-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGEM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667644374","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Molina Healthcare (MOH), High Tide (HITI) and Cullinan Management (CGEM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2667644374","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667644374?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:40","pubTimestamp":1789472436,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Molina Healthcare (MOH), High Tide (HITI) and Cull...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-molina-healthcare-moh-high-tide-hiti-and-cullinan-management-cgem-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-molina-healthcare-moh-high-tide-hiti-and-cullinan-management-cgem-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","MOH","BK4585","PSCH","HITI","SG9999014005.SGD","SG9999014021.USD","BK4532","SG9999014013.SGD","BK4139","XBI","CGEM","LABU","XLV","SG9999014039.USD","BK4154","BK4007","BK4581"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cullinantherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0473},{"period":"1month","weight":-0.3054},{"period":"3month","weight":-0.1202},{"period":"6month","weight":0.0748},{"period":"1year","weight":1.6974},{"period":"ytd","weight":0.4986}],"compareEarnings":[{"period":"1week","weight":-0.0022},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0334},{"period":"6month","weight":0.1735},{"period":"1year","weight":0.1501},{"period":"ytd","weight":0.1286}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cullinan Oncology, Inc. a clinical-stage biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally bioavailable small-molecule that is in a Phase IIb dose escalation for treating patients with non-small cell lung cancer. Its products also include CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors; and CLN-418, a human bispecific antibody that is in Phase 1 clinical trial for the treatment of solid tumors. In addition, the company's preclinical product includes CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.097052},{"month":2,"riseRate":0.666667,"avgChangeRate":0.069507},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.100308},{"month":4,"riseRate":0.333333,"avgChangeRate":0.044053},{"month":5,"riseRate":0.666667,"avgChangeRate":0.039338},{"month":6,"riseRate":0.5,"avgChangeRate":-0.027852},{"month":7,"riseRate":0.5,"avgChangeRate":-0.004001},{"month":8,"riseRate":0.5,"avgChangeRate":0.087786},{"month":9,"riseRate":0,"avgChangeRate":-0.173118},{"month":10,"riseRate":0.666667,"avgChangeRate":0.07335},{"month":11,"riseRate":0.2,"avgChangeRate":-0.037651},{"month":12,"riseRate":0.2,"avgChangeRate":-0.046792}],"exchange":"NASDAQ","name":"Cullinan Therapeutics","nameEN":"Cullinan Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cullinan Therapeutics(CGEM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cullinan Therapeutics(CGEM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cullinan Therapeutics,CGEM,Cullinan Therapeutics股票,Cullinan Therapeutics股票老虎,Cullinan Therapeutics股票老虎国际,Cullinan Therapeutics行情,Cullinan Therapeutics股票行情,Cullinan Therapeutics股价,Cullinan Therapeutics股市,Cullinan Therapeutics股票价格,Cullinan Therapeutics股票交易,Cullinan Therapeutics股票购买,Cullinan Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cullinan Therapeutics(CGEM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cullinan Therapeutics(CGEM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction